Cambridge-based Valink Therapeutics closed an $11.8M pre‑A financing to advance its bispecific antibody-drug conjugates and oncology programs. The round was led by redalpine with participation from LongeVC, Oxford Science Enterprises and existing backers RV Invest and p53 Invest.
Comments
Want to join the conversation?
Loading comments...